Alzheimer's Disease and Parkinson's Disease
Open accessThe DOI matches its Crossref record; 106 of the 107 references it cites were found in a registry or an index.
Abstract
Although most cases of Alzheimer's and Parkinson's disease are sporadic, some cases are clearly familial. This review, part of the Genomic Medicine series, examines the genetics of these familial forms. Although the inherited forms are rare, the knowledge derived from investigating their pathobiology has improved our understanding of the pathobiology of the more common, sporadic forms of the diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general terms, neurodegenerative diseases are thought to be driven by the accumulation of neurotoxic material such as amyloid beta (Aβ) or myelin debris in the central nervous system (CNS) (Nussbaum and Ellis, 2003; Trapp and Nave, 2008).”
From SYK coordinates neuroprotective microglial responses in neurodegenerative disease (2022) · cites this paper as Nussbaum and Ellis, 2003
In the citing paper
“PD pathology is mainly characterized by loss of neurons from the substantia nigra pars compacta in association with the accumulation of ubiquitinated alpha synuclein and other proteins in cytoplasmic inclusions (Lewy bodies) and thread-like proteinaceous inclusions within neurites (Lewy neuritis).”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“However, Lewy bodies are also seen in the cerebral cortex, brainstem nuclei, limbic system, sympathetic ganglia, nucleus basalis of Meinert and myenteric plexus [4].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [4]
In the citing paper
“This review is focused on the potential of herbal medicine in AD since it is responsible for more than two-thirds of all dementia cases [5,6].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [6]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 4×
“Increased Abeta42(43) from cell lines expressing presenilin 1 mutations.”
BackgroundInfluentialSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Self-citationMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Research works printed but not linked: 5
- 10.1001/archinte.151.5.989 · doi:10.1001/archinte.151.5.989 · Paper page
- Clark CM, Ewbank D, Lee VM-Y, Trojanowski JQ. Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. In: Growdon JH, Rossor MN, eds. The dementias. Vol. 19 of Blue books of practical neurology. Boston: Butterworth–Heinemann, 1998:285-304.
- Duvoisin RC, 1996, Adv Neurol, 69, 33
- Louis ED, 1996, Adv Neurol, 69, 311
- Matsumine H, 1997, Am J Hum Genet, 60, 588
Cited by
Items 301–400 of 1,000
Deciding to Institutionalize: Why Do Family Members Cease Caregiving at Home?
McLennon, S. M., Habermann, B., & Davis, L. L. (2010) · Journal of Neuroscience Nursing · doi:10.1097/jnn.0b013e3181ce5c45 · Cited by 69
“The most common form of neurodegenerative dis-ease is dementia, of which Alzheimer dis-ease (AD) comprises two thirds of the cases (Nussbaum & Ellis, 2003).”
BackgroundZhou, D., Noviello, C., D'Ambrosio, C., Scaloni, A., & D'Adamio, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400488200 · Cited by 59
Oliveira-Giacomelli, Á., M. Albino, C., de Souza, H. D. N., Corrêa-Velloso, J., de Jesus Santos, A. P., Baranova, J., & Ulrich, H. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00476 · Cited by 60
“Parkinson’s disease (PD) is highly incapacitating and affects nearly 1% of individuals between 65 and 69 years, reaching almost 3% of individuals after 80 years of age (Nussbaum and Ellis, 2003).”
BackgroundMahendran, N., Vincent, P. M. D. R., Srinivasan, K., & Chang, C. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.784814 · Cited by 63
“The term progressive concerning AD means it gets worse over time because of irreversible degeneration of neurons (neurodegenerative) (Nussbaum and Ellis, 2003).”
BackgroundLiu, H., Zheng, M., Du, Y., Wang, L., Kuang, F., Qin, H., Zhang, B., & Han, H. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.06.001 · Cited by 67
Degeneration of mesencephalic dopaminergic neurons in klotho mouse related to vitamin D exposure
Kosakai, A., Ito, D., Nihei, Y., Yamashita, S., Okada, Y., Takahashi, K., & Suzuki, N. (2011) · Brain Research · doi:10.1016/j.brainres.2011.01.056 · Cited by 64
Hung, W., Ho, C., & Pan, M. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900550 · Cited by 66
Balkrishna, A., Sakshi, Chauhan, M., Dabas, A., & Arya, V. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/5359669 · Cited by 59
Dysregulation of tyrosinase activity: a potential link between skin disorders and neurodegeneration
Jin, W., Stehbens, S. J., Barnard, R. T., Blaskovich, M. A. T., & Ziora, Z. M. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgad107 · Cited by 64
Morais, L. H., Hara, D. B., Bicca, M. A., Poli, A., & Takahashi, R. N. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000389 · Cited by 58
Liu, Z., Chan, R., Cai, Z., Liu, X., Wu, Y., Yu, Z., Feng, T., Yang, Y., & Zhang, J. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02413-1 · Cited by 59
Oskouei, M. M., Hamidi, F., Talebi, M., Farhoudi, M., Taheraghdam, A. A., Kazemi, T., Sadeghi‐Bazargani, H., & Fallah, E. (2016) · Parasitology Research · doi:10.1007/s00436-016-5075-5 · Cited by 60
“Alzheimer is an important nervous disease that results in irreversible loss of neurons in the cortex and hippocampus of the brain and it includes about two thirds of all cases of dementia (Guttmacher et al. 2003).”
The Role of Mitochondrial Aldehyde Dehydrogenase 2 (ALDH2) in Neuropathology and Neurodegeneration.
Chen, C., Joshi, A. U., & Mochly‐Rosen, D. (2016) · PubMed · Cited by 80
Role of Medicinal Plants against Neurodegenerative Diseases
Luthra, R., & Roy, A. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210211123539 · Cited by 63
Comparison Analysis of Gene Expression Patterns between Sporadic Alzheimer's and Parkinson's Disease
Grünblatt, E., Zander, N., Bartl, J., Li, J., Monoranu, C., Arzberger, T., Ravid, R., Roggendorf, W., Gerlach, M., & Riederer, P. F. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-12402 · Cited by 63
Antioxidant strategies in protection against neurodegenerative disorders
Tan, D.-X., Manchester, L. C., Sainz, R. M., Mayo, J. C., Alvares, F. L., & Reiter, R. J. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.10.1513 · Cited by 64
Considerations for general anaesthesia in Parkinson’s disease
Roberts, D. P., & Lewis, S. J. G. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.10.062 · Cited by 60
The role of NURR1 in metabolic abnormalities of Parkinson’s disease
Al‐Nusaif, M., Yang, Y., Li, S., Cheng, C., & Le, W. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00544-w · Cited by 57
The MC1R melanoma risk variant p. R160W is associated with P arkinson disease
Tell‐Martí, G., Puig‐Butillé, J. A., Potrony, M., Bádenas, C., Milà, M., Malvehy, J., Martí, M. J., Ezquerra, M., Fernández‐Santiago, R., & Puig, S. (2015) · Annals of Neurology · doi:10.1002/ana.24373 · Cited by 61
Donepezil: a clinical review of current and emerging indications
Román, G. C., & Rogers, S. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.1.161 · Cited by 58
Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes
Vacic, V., Ozelius, L. J., Clark, L. N., Bar‐Shira, A., Gana‐Weisz, M., Gurevich, T., Gusev, A., Kedmi, M., Kenny, E. E., Liu, X., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu158 · Cited by 63
Destigmatising dementia: The dangers of felt stigma and benevolent othering
Fletcher, J. R. (2019) · Dementia · doi:10.1177/1471301219884821 · Cited by 64
“The Alzheimer’s Society (2019) currently lists 13 ambassadors living with dementia, of which two were diagnosed in their 40s, nine in their 50s and two in their 60s, while the average age of dementia onset is 80 (Nussbaum & Ellis, 2003).”
BackgroundTherapeutic RNA interference for neurodegenerative diseases: From promise to progress
Gonzalez‐Alegre, P. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.003 · Cited by 62
New Genetic Insights into Parkinson's Disease
Feany, M. Β. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048263 · Cited by 56
Peña‐Díaz, S., García‐Pardo, J., & Ventura, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030839 · Cited by 60
“PD is considered to be the world’s second most prevalent neurodegenerative disorder, after AD [14,15].”
BackgroundShim, B., Landerman, L. R., & Davis, L. L. (2011) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.2011.05618.x · Cited by 61
Socías, S. B., González‐Lizárraga, F., Ávila, C. L., Vera, C., Acuña, L., Sepulveda-Diaz, J. E., Bel, E. A. D., Raisman‐Vozari, R., & Chehín, R. N. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.12.002 · Cited by 60
“These inclusions are predominantly formed by a-synuclein in a misfolded fibrillary stage (Bennett, 2005; Nussbaum and Ellis, 2003; Ruzza et al., 2014; Spillantini et al., 1998).”
BackgroundWang, C.-C., Hu, X., Long, Y.-F., Huang, H.-R., He, Y., Xu, Z., & Qi, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123014 · Cited by 56
Allele-specific RNAi Mitigates Phenotypic Progression in a Transgenic Model of Alzheimer's Disease
Rodríguez-Lebrón, E., Gouvion, C. M., Moore, S. A., Davidson, B. L., & Paulson, H. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.123 · Cited by 58
Selenium reduces bradykinesia and DNA damage in a rat model of Parkinson's disease
Ellwanger, J. H., Molz, P., Dallemole, D. R., dos Santos, A. P., Müller, T. E., Cappelletti, L., da Silva, M. G., Franke, S. I. R., Prá, D., & Henriques, J. A. P. (2014) · Nutrition · doi:10.1016/j.nut.2014.07.004 · Cited by 54
“3% among the general population in industrialized countries and about 1% among people>60 y of age [1,2].”
BackgroundFuruya, T. K., Silva, P. N., Payão, S. L. M., Bertolucci, P. H. F., Rasmussen, L. T., de Lábio, R. W., Braga, I. L. S., Chen, E., Turecki, G., Mechawar, N., et al. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.06.035 · Cited by 58
“This irreversible loss of neurons occurs particularly in the cortex and hippocampus areas in the brain (Nussbaum and Ellis, 2003).”
BackgroundGastrointestinal Dysfunction in Parkinson’s Disease: Current and Potential Therapeutics
Han, M. N., Finkelstein, D. I., McQuade, R. M., & Diwakarla, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020144 · Cited by 59
DNA methylation in neurodegenerative disorders: a missing link between genome and environment?
Iraola-Guzmán, S., Estivill, X., & Rabionet, R. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01673.x · Cited by 52
Jörg, M., May, L. T., Mak, F. S., Lee, K. C. K., Miller, N. D., Scammells, P. J., & Capuano, B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501254d · Cited by 53
Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer’s Disease
Kwak, K.-A., Lee, S., Yang, J.-Y., & Park, Y. (2018) · Stem Cells International · doi:10.1155/2018/6392986 · Cited by 54
Jiang, L., Li, X., Mortadza, S. A. S., Lovatt, M., & Yang, W. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.002 · Cited by 55
Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease
Liu, J., Xu, F., Nie, Z., & Shao, L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.570658 · Cited by 55
Oudsten, B. L. D., Lucas, R., Green, A. M., & The Whoqol-Dis Group (2011) · Disability and Rehabilitation · doi:10.3109/09638288.2011.575527 · Cited by 66
Bernardini, S., Bellincampi, L., Ballerini, S., Federici, G., Iori, R., Trequattrini, A., Ciappi, F., Baldinetti, F., Bossù, P., Caltagirone, C., et al. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.045955 · Cited by 56
Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease
Hamshere, M. L., Holmans, P. A., Avramopoulos, D., Bassett, S. S., Blacker, D., Bertram, L., Wiener, H., Rochberg, N., Tanzi, R. E., Myers, A., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm224 · Cited by 54
Papadopoulos, A., Iakovakis, D., Klingelhoefer, L., Bostantjopoulou, S., Chaudhuri, K. R., Kyritsis, K., Hadjidimitriou, S., Charisis, V., Hadjileontiadis, L. J., & Delopoulos, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-78418-8 · Cited by 51
CD 4+ T cells in the pathobiology of neurodegenerative disorders
Huang, X., Reynolds, A. D., Mosley, R. L., & Gendelman, H. E. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.04.006 · Cited by 56
Genetic aspects of Alzheimer's disease
Żekanowski, C., Religa, D., Graff, C., Filipek, S., & Kuźnicki, J. (2004) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2004-1488 · Cited by 55
APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease
Tropea, T. F., Xie, S. X., Rick, J., Chahine, L. M., Dahodwala, N., Doshi, J., Davatzikos, C., Shaw, L. M., Van Deerlin, V., Trojanowski, J. Q., et al. (2018) · Movement Disorders · doi:10.1002/mds.27204 · Cited by 50
Bali, N. R., & Salve, P. S. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.261 · Cited by 52
Vacchi, E., Kaelin‐Lang, A., & Melli, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145030 · Cited by 56
“The most common human neurodegenerative affections are Alzheimer’s disease (AD) and Parkinson’s disease (PD), which respectively represent the first and second neurodegenerative disease in the elderly [1].”
BackgroundClinical and Imaging Progression in the PARS Cohort: Long‐Term Follow‐up
Siderowf, A. D., Jennings, D. L., Stern, M., Seibyl, J. P., Eberly, S. W., Oakes, D., MAREK, K. L., & for the PARS Investigators (2020) · Movement Disorders · doi:10.1002/mds.28139 · Cited by 53
Saka, R., Chella, N., & Khan, W. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-021-02072-0 · Cited by 53
Walia, V., Chaudhary, S. K., & Kumar Sethiya, N. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2020.104939 · Cited by 51
Neuroregulatory role of ginkgolides
Gachowska, M., Szlasa, W., Saczko, J., & Kulbacka, J. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06535-2 · Cited by 53
MicroRNAs in Parkinson’s disease: a systematic review and diagnostic accuracy meta-analysis
Guévremont, D., Roy, J., Cutfield, N. J., & Williams, J. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-43096-9 · Cited by 56
Kum, W. F., Durairajan, S. S. K., Bian, Z. X., Man, S. C., Lam, Y. C., Xie, L., Lu, J., Wang, Y., Huang, X. Z., & Li, M. (2009) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nep116 · Cited by 51
Wang, I., Lin, C., Wu, Y., Chou, C., Lin, S., Liu, J.-H., Yen, T., Huang, C.-C., & Sung, F. (2014) · Neuroepidemiology · doi:10.1159/000358921 · Cited by 53
A bicentric controlled study on the effects of aquatic Ai Chi in Parkinson disease
la Cruz, S. P. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.12.001 · Cited by 54
Qureshi, A. R., Rana, A. Q., Malik, S. H., Rizvi, S. F. H., Akhter, S., Vannabouathong, C., Sarfraz, Z., & Rana, R. (2018) · Neuroepidemiology · doi:10.1159/000492221 · Cited by 52
Lidman, O., Swanberg, M., Horvath, L., Broman, K. W., Olsson, T., & Piehl, F. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-30-09817.2003 · Cited by 51
Markov, N. T., Lindbergh, C. A., Staffaroni, A. M., Pérez, K., Stevens, M., Nguyen, K., Murad, N. F., Fonseca, C. S., Campisi, J., Kramer, J. H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2207181119 · Cited by 52
Othman, A. A., & Dutta, S. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12324 · Cited by 50
A new outlook on cholinergic interneurons in Parkinson’s disease and L-DOPA-induced dyskinesia
Conti, M. M., Chambers, N., & Bishop, C. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.05.021 · Cited by 50
Sohur, U. S., Gray, D. L., Duvvuri, S., Zhang, Y., Thayer, K., & Feng, G. (2018) · Neurology and Therapy · doi:10.1007/s40120-018-0114-z · Cited by 50
Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases
Seo, M., & Park, T. (2021) · Biomedical Engineering Letters · doi:10.1007/s13534-021-00198-5 · Cited by 52
Pike, A. F., Szabó, I., Veerhuis, R., & Bubacco, L. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00293-z · Cited by 52
Immunology, Autoimmunity, and Autoantibodies in Parkinson’s Disease
Benkler, M., Agmon‐Levin, N., Hassin‐Baer, S., Cohen, O. S., Ortega‐Hernandez, O., Levy, A., Moscavitch, S.-D., Szyper‐Kravitz, M., Damianovich, M., Blank, M., et al. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8242-y · Cited by 50
“Parkinson’s disease (PD) is a common progressive neurodegenerative disorder, which has immerged as a primary focus of interest due to its increasing prevalence, debilitating features, and decrease in age of onset [1].”
BackgroundXue, S., & Jia, J. (2006) · Brain Research · doi:10.1016/j.brainres.2006.02.121 · Cited by 52
- α-Synuclein and Parkinson’s Disease
(2012) · Parkinson's Disease · doi:10.1201/b12948-15 · Cited by 50
Coconut oil as a therapeutic treatment for alzheimer's disease: a review
Sandupama, P., Munasinghe, D., & Jayasinghe, M. A. (2022) · Journal of Future Foods · doi:10.1016/j.jfutfo.2022.03.016 · Cited by 55
Neuroprotective Effects of Lactoferrin in Alzheimer’s and Parkinson’s Diseases: A Narrative Review
Yong, S. J., Veerakumarasivam, A., Lim, W. L., & Chew, J. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00679 · Cited by 54
Cognitive and Neuropsychiatric Features of Early Parkinson's Disease
Getz, S. J., & Levin, B. E. (2017) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acx091 · Cited by 52
“In industrialized countries, PD prevalence is estimated at 0.3% of the entire population and at about 1% in individuals over 60 years of age (Nussbaum & Ellis, 2003).”
BackgroundInfluentialRoles of β-adrenergic receptors in Alzheimer's disease: Implications for novel therapeutics
Yu, J., Wang, N., Ma, T., Jiang, H. F., Guan, J., & Tan, L. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.11.004 · Cited by 55
Diseases of protein aggregation and the hunt for potential pharmacological agents
Wang, S. S. ‐., Wu, J. W., Yamamoto, S., & Liu, H. (2008) · Biotechnology Journal · doi:10.1002/biot.200700065 · Cited by 49
Lin, K., Jie, B., Dong, P., Ding, X., Bian, W., & Liu, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.933660 · Cited by 55
Lee, K.-S., Lee, W., & Hwang, S. (2011) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e31820b15cd · Cited by 48
Nilsson, M. H., Patel, M., Rehncrona, S., Magnusson, M., & Fransson, P.-A. (2013) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/1743-0003-10-33 · Cited by 48
Advances in Nanomedicine for the Treatment of Alzheimer’s and Parkinson’s Diseases
Hernando, S., Gartziandia, O., Herran, E., Pedraz, J. L., Igartua, M., & Hernandez, R. M. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0019 · Cited by 48
Effects of Ginkgo Biloba Extract on A53T α-Synuclein Transgenic Mouse Models of Parkinson’s Disease
Kuang, S., Yang, L., Rao, Z., Zhong, Z., Li, J., Zhong, H., Dai, L., & Tang, X. (2017) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2017.268 · Cited by 48
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Han, Z., Tian, R., Ren, P., Zhou, W., Wang, P., Luo, M., Jin, S., & Jiang, Q. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0721-7 · Cited by 51
“Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the top two common neurodegenerative diseases [1].”
BackgroundOrtiz‐Guerrero, G., González-Reyes, R. E., de‐la‐Torre, A., Medina-Rincón, G. J., & Nava-Mesa, M. O. (2020) · Brain Sciences · doi:10.3390/brainsci10060369 · Cited by 50
“It accounts for two‐ thirds of all dementia cases and affects 7% of people older than 65 years and 40% of people older than 80 years [3].”
BackgroundParkinson’s Disease, Periodontitis and Patient-Related Outcomes: A Cross-Sectional Study
Lyra, P., Machado, V., Proença, L., Domingos, J., Godinho, C., Mendes, J. J., & Botelho, J. (2020) · Medicina · doi:10.3390/medicina56080383 · Cited by 55
“PD motor symptoms such as resting tremor, rigidity and bradykinesia are all commonly targeted by the standard available therapies, which include dopaminergic drugs and functional neurosurgery [1,5].”
BackgroundAybek, H., Ercan, F., Aslan, D., & Şahiner, T. (2006) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2006.09.005 · Cited by 52
Mitochondrial Alterations and Neuropsychiatric Disorders
Marazziti, D., Baroni, S., Picchetti, M., Landi, P., Silvestri, S., Vatteroni, E., & Catena Dell'Osso, M. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797379221 · Cited by 44
Spoken language biomarkers for detecting cognitive impairment
Alhanai, T., Au, R., & Glass, J. R. (2017) · IEEE Workshop on Automatic Speech Recognition and Understanding (ASRU) · doi:10.1109/asru.2017.8268965 · Cited by 56
Ebrahimi, A., Ahmadi, H., Ghasrodashti, Z. P., Tanide, N., Shahriarirad, R., Erfani, A., Ranjbar, K., & Ashkani‐Esfahani, S. (2021) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2021.5508 · Cited by 56
An effective novel delivery strategy of rasagiline for Parkinson's disease
Fernández, M., Negro, S., Slowing, K., Fernández-Carballido, A. M., & Barcia, E. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.029 · Cited by 54
Multimodal Voxel-Based Meta-Analysis of White Matter Abnormalities in Alzheimer’s Disease
Yin, R.-H., Tan, L., Liu, Y., Wang, W.-Y., Wang, H.-F., Jiang, T., Raduà, J., Zhang, Y., Gao, J., Canu, E., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150139 · Cited by 51
Li, K., Zhang, J., Ji, C., & Wang, L. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.0050 · Cited by 48
Sun, Y., Pham, A. N., Hare, D. J., & Waite, T. D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00859 · Cited by 50
Early intervention attenuates synaptic plasticity impairment and neuroinflammation in 5xFAD mice
Li, K., Wang, X., Jiang, Y., Zhang, X., Liu, Z., Yin, T., & Yang, Z. R. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.007 · Cited by 48
Albiol-Pérez, S., Gil‐Gómez, J., Muñoz-Tomás, M.-T., Gil-Gómez, H., Escolano, R. V., & Lozano-Quilis, J.-A. (2017) · Methods of Information in Medicine · doi:10.3414/me16-02-0004 · Cited by 49
Scheinfeld, M. H., Ghersi, E., Davies, P., & D'Adamio, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304853200 · Cited by 45
Insights on the Use of Transgenic Mice Models in Alzheimer’s Disease Research
Pádua, M. S., Guil-Guerrero, J. L., Prates, J. A. M., & Lopes, P. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052805 · Cited by 46
Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors
Lindsley, S. R., Moore, K. P., Rajapakse, H. A., Selnick, H. G., Young, M. B., Zhu, H., Munshi, S. K., Kuo, L. C., McGaughey, G. B., Colussi, D. J., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.072 · Cited by 51
Hendy, A. M., Tillman, A., Rantalainen, T., Muthalib, M., Johnson, L., Kidgell, D. J., Wundersitz, D., Enticott, P. G., & Teo, W.-P. (2016) · Trials · doi:10.1186/s13063-016-1461-7 · Cited by 46
Liu, F., Yang, X., Ma, J., Yang, Y., Xie, C., Tuerhong, M., Jin, D., Xu, J., Lee, D., Ohizumi, Y., et al. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.09.007 · Cited by 46
Silva, P., Sureda, A., Tur, J. A., Andreoletti, P., Cherkaoui‐Malki, M., & Latruffe, N. (2019) · Free Radical Research · doi:10.1080/10715762.2019.1614176 · Cited by 48
“increase, neuronal apoptosis activation, aggregated proteins deposition, and excite-toxicity [23].”
BackgroundToxoplasma gondii: A possible etiologic agent for Alzheimer's disease
Nayeri, T., Sarvi, S., Sharif, M., & Daryani, A. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e07151 · Cited by 47
“The AD is characterized by dystrophic neuritis [5], irreversible loss of neurons in the cortex and hippocampus [6], granulovacuolar degeneration [7], amyloid-beta (Aβ) plaques caused by the aggregation of Aβ1-42 peptide, neurofibrillary tangles (NFTs) formed by a microtubule-associated protein [8, 9], synaptic dysfunc…”
Blocking β2-adrenergic receptor attenuates acute stress-induced amyloid β peptides production
Yu, N., Wang, X., Yu, J., Wang, N., Lu, R.-C., Miao, D., Tian, Y., & Tan, L. (2010) · Brain Research · doi:10.1016/j.brainres.2009.12.087 · Cited by 51
Alzheimer’s Disease and Genetics of Inflammation: A Pharmacogenomic Vision
Vasto, S., Candore, G., Duro, G., Lio, D., Grimaldi, M. P., & Caruso, C. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.12.1735 · Cited by 46
Voltage-gated calcium channels and Parkinson's disease
Hurley, M. J., & Dexter, D. T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.006 · Cited by 55
Zeng, Q., Liu, P., Yu, N., Wu, J., Huo, W., & Han, J. (2023) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2023.3291359 · Cited by 50
Activated Immune Cells in Parkinson's Disease
Cao, J., Li, K., & Shen, Y. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9280-9 · Cited by 47
Metadata
- Authors
- Nussbaum, R. L., & Ellis, C. E.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Nussbaum, Robert L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1356-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149522871
- Cited by
- 1,351
- References
- 107
- Citations by year
- 2026: 25 · 2025: 55 · 2024: 75 · 2023: 74 · 2022: 80 · 2021: 82 · 2020: 80 · 2019: 83 · 2018: 74 · 2017: 74 · 2016: 63 · 2015: 54 · 2014: 65 · 2013: 46 · 2012: 66
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, Parkinson's disease, genetic susceptibility, inherited neurodegenerative disorders
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Apolipoproteins E, Humans, Molecular Sequence Data, Nerve Tissue Proteins, Substantia Nigra, Prevalence, Amyloid beta-Protein Precursor, Lewy Bodies, Mutation, Missense, Parkinsonian Disorders, Synucleins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.